Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

"New Hope for Ovarian Cancer Patients: Experimental Drug Shows Promise. Researchers have made a groundbreaking discovery that could significantly improve the lives of women with platinum-resistant ovarian cancer, an aggressive and often deadly form of the disease. Relacorilant, a medication typically used to treat Cushing's syndrome, has shown remarkable results in a recent clinical trial, offering a glimmer of hope for patients who have exhausted traditional treatment options. With platinum-based chemotherapy often failing to slow the progression of this disease, the potential of Relacorilant to extend lives and improve outcomes is a major breakthrough, and further research is eagerly anticipated."

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant casesA drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing. Continue reading...